SEC Form 4 · accession 0001610717-26-000229
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Ogden
Officer — Chief Financial Officer
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 6:38 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 15, 2026 | S | 1,624 | $3.05 | D | 295,324 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- F2Includes 167,249 RSUs.